Exact Sciences had its Relative Strength (RS) Rating upgraded from 77 to 84 Thursday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an 80 or better RS Rating in the early stages of their moves.
Exact Sciences is building a cup without handle with a 72.83 buy point. See if it can clear the breakout price in volume at least 40% above average.
Exact Sciences reported 0% EPS growth in its most recent report, while sales growth came in at 11%.
The company earns the No. 38 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and Eton Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
